公开(公告)号：US20190135910A1

公开(公告)日：2019-05-09

申请号：US16181733

申请日：2018-11-06

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Lillian Xu

IPC: C07K16/24 ,  A61P19/02 ,  A61K47/68 ,  G16H50/30 ,  A61K9/00

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, PASI70/90/100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI/dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20220025035A1

公开(公告)日：2022-01-27

申请号：US17373866

申请日：2021-07-13

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Xie Xu ,  Alexa Kollmeier ,  Bei Zhou

IPC: C07K16/24 ,  A61P29/00

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16 and 24 weeks after initial treatment.

公开(公告)号：US20230340103A1

公开(公告)日：2023-10-26

申请号：US18166878

申请日：2023-02-09

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Alexa Kollmeier ,  Xie Xu

IPC: C07K16/24 ,  A61P19/02

CPC classification number: C07K16/244 ,  A61P19/02 ,  C07K2317/21 ,  C07K2317/56

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant improvement in clinical endpoints, such as ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis, as measured 16 and 24 weeks after initial treatment.

公开(公告)号：US20220298236A1

公开(公告)日：2022-09-22

申请号：US17691182

申请日：2022-03-10

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Alexa Kollmeier ,  Xie Ku

IPC: C07K16/24 ,  A61P19/02 ,  A61P37/06

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16, 24, 52, and/or 100 weeks after initial treatment.

公开(公告)号：US20210363235A1

公开(公告)日：2021-11-25

申请号：US17385284

申请日：2021-07-26

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Xie Xu

IPC: C07K16/24 ,  A61P19/02 ,  A61K9/00 ,  G16H50/30 ,  A61K47/68 ,  A61K47/18 ,  A61K47/26

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, PASI70/90/100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI/dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.